Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study).
Yang Y, Zhou T, Chen X, Li J, Pan J, He X, Lin L, Shi YR, Feng W, Xiong J, Yang K, Yu Q, Zhang Q, Hu D, Sun Y, Hu G, Li P, Shen L, Lin Q, Zhang B, Qu X, Zou J, Zhang L, Fang W, Zhao Y.
Yang Y, et al. Among authors: zhao y.
J Immunother Cancer. 2021 Dec;9(12):e003790. doi: 10.1136/jitc-2021-003790.
J Immunother Cancer. 2021.
PMID: 34933967
Free PMC article.
Clinical Trial.